These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12876542)

  • 1. [Telithromycin in the management of lower respiratory tract infections in the hospital].
    Léophonte P
    Presse Med; 2003 Jun; 32(20):952-3. PubMed ID: 12876542
    [No Abstract]   [Full Text] [Related]  

  • 2. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telithromycin (Ketek) for respiratory infections.
    Med Lett Drugs Ther; 2004 Aug; 46(1189):66-8. PubMed ID: 15314586
    [No Abstract]   [Full Text] [Related]  

  • 5. [Telithromycin: a new therapeutic option for community-acquired respiratory infection].
    Muñoz MJ; Azanza JR; Escolar M; Macaya A; Gil FJ
    Rev Med Univ Navarra; 2002; 46(3):37-44. PubMed ID: 12685116
    [No Abstract]   [Full Text] [Related]  

  • 6. [Telithromycin, a once-a-day ketolide in the treatment of community acquired pneumonia].
    Carbon C
    Presse Med; 2000 Dec; 29(37):2042-3. PubMed ID: 11155730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Importance in respiratory tract infections. Ketolides: clinical aspects].
    Lorenz J; Steiert P
    Pharm Unserer Zeit; 2004; 33(1):42-6. PubMed ID: 14968712
    [No Abstract]   [Full Text] [Related]  

  • 12. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM; Visser M; Mac Dougall N; Coco B; Tomé G; Gliosca L;
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of telithromycin and beta-lactam antimicrobials against bacterial pathogens from community-acquired respiratory tract infections: data from the first year of PROTEKT (1999-2000).
    Kohno S; Hoban D;
    J Chemother; 2003 Aug; 15(4):335-41. PubMed ID: 12962361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae.
    Okamoto H; Miyazaki S; Tateda K; Ishii Y; Yamaguchi K
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3250-2. PubMed ID: 11600393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bacterial airway infections. Standard antibiotics more often ineffective].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910829
    [No Abstract]   [Full Text] [Related]  

  • 16. Telithromycin versus clarithromycin for the treatment of community-acquired respiratory tract infections: a meta-analysis of randomized controlled trials.
    Li XM; Wang FC; Yang F; Jin YH
    Chin Med J (Engl); 2013; 126(11):2179-85. PubMed ID: 23769580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new antibiotic against respiratory tract infections. More power against pneumococci].
    MMW Fortschr Med; 2001 Nov; 143(44):59. PubMed ID: 11732406
    [No Abstract]   [Full Text] [Related]  

  • 18. Will resistance to ketolides develop in Streptococcus pneumoniae?
    Leclercq R
    J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance of respiratory tract infection agents is still increasing. Is its time for new antibiotic strategies?].
    MMW Fortschr Med; 2003 Feb; 145(9):55. PubMed ID: 12666535
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy trial in general practice substantiated. New antibiotic with strong effectiveness and tolerance].
    MMW Fortschr Med; 2002 Oct; 144(42):60-1. PubMed ID: 12534000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.